|
|
|
|
| This event offers short, interactive digital presentations from leading CDMOs showcasing their capabilities, facilities, and available capacity for biopharma development and fill-finish manufacturing. Attendees can explore sterile filling, lyophilization, and packaging technologies, and ask questions live. Open to pharma and biotech professionals, industry consultants, investment firms, and CDMO sponsors seeking manufacturing solutions. Click here to learn more. |
|
|
|
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | CDMOs have valid reasons for it. Professionals on both sides say external development and manufacturing organizations want to be viewed in a better light by sponsors. Recruiting experienced sponsor-side professionals is one step to accomplishing that goal. Not exactly new, but intensified in 2025. And expect more in 2026. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
TPDs: Developing The Next Generation Of Oral Therapeutics | Article | By Anshul Gupte, Ph.D., PCI Pharma Services | Targeted Protein Degraders are a revolutionary drug class with challenges in bioavailability and formulation complexity. Strategic CDMO partnerships are key to successful, scalable development. |
|
|
|
|
|
|
|
Fast-Track Your Antibody Drug Conjugate | Simtra BioPharma Solutions | Accelerate the development of ADCs with capabilities spanning clinical to commercial production, including OEB 5 handling, state-of-the-art fill/finish, and future expanded conjugation services. |
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|